Mankind Pharma Limited — PPTs, 03-02-2026: Investor Presentation

Mankind Pharma reported strong Q3FY26 results with revenue up 11.5% YoY to ₹3,567 Cr and Profit After Tax (PAT) increasing 9.5% to ₹414 Cr. Domestic business grew 11.1% to ₹3,046 Cr, while Exports saw a robust 14.1% jump to ₹521 Cr.

Growth is propelled by an increasing chronic share, now at 39.3%, driven by strong performance in Cardiac (+16.7%) and Anti-Diabetics (+14.4%). The Consumer Healthcare segment is regaining momentum with 5.2% growth, boosted by key brands and expanding digital channels. Strategic integration of BSV's super specialty portfolio and new in-licensing deals (like Crenzlo and Symbicort) are set to drive future expansion.

Adjusted EBITDA margins stood at 25.9% for the quarter, and Diluted EPS was ₹9.9, up 6.7% YoY. Management remains confident in delivering sustainable long-term growth by leveraging its steady base business, fast-growing specialty chronic, high-potential OTC, and BSV portfolio, with a higher focus on R&D and digital platforms. #MankindPharma #Q3Results #Pharma